TP53突变在新诊断弥漫性大B细胞淋巴瘤患者中的预后影响:FIL-DLCL04试验分析
该分析纳入FIL-DLCL04试验中125例有肿瘤组织块的新诊断弥漫性大B细胞淋巴瘤患者,采用Sanger测序检测TP53突变,并分析细胞起源、MYC/BCL2/BCL6过表达或重排与预后的关系。中位随访72个月,TP53突变型与野生型相比5年无失败生存率分别为24%和72%,5年总生存率分别为34%和83%。调整后风险比(HR)无失败生存为2.28(95%CI 0.89-5.86,p=0.086),总生存为4.05(95%CI 1.37-11.97,p=0.011)。
要点
- TP53突变见于11/125(9%)例患者。
- TP53突变型5年无失败生存率24%,野生型72%。
- TP53突变型5年总生存率34%,野生型83%。
核心结论
- 在这组年轻弥漫性大B细胞淋巴瘤患者中,TP53基因突变识别出一个预后不良亚组,与治疗和其他生物学标志物无关。
研究设计与样本
- 研究纳入FIL-DLCL04试验(NCT00499018)中125例有肿瘤组织块可用的弥漫性大B细胞淋巴瘤患者。
- 采用Sanger测序检测TP53突变,Lymph2Cx panel在NanoString平台分析细胞起源,免疫组化和荧光原位杂交评估MYC、BCL2、BCL6过表达或重排。
主要发现
- TP53在11/125(9%)例中突变。
- 60/125例患者 upfront 接受了大剂量化学免疫治疗,按随机化分组。
- 细胞起源在88例中报告:48例生发中心B细胞样,25例活化B细胞样,17例未分类。
- 26例为免疫组化双表达,11例为荧光原位杂交双打击。
- 中位随访72个月,TP53突变型 vs 野生型的5年无失败生存率分别为24%和72%,5年总生存率分别为34%和83%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognostic role of TP53 disruption has been established in diffuse large B-cell lymphoma (DLBCL). Aim of this analysis was to correlate TP53 mutations by Sanger sequencing, cell of origin (COO) profile by Lymph2Cx panel on the NanoString platform and MYC, BCL2 and BCL6 overexpression or re-arrangements by immunohistochemistry (IHC) and fluorescent in-situ hybridization (FISH), with outcome in DLBCL patients enrolled into the FIL-DLCL04 trial (NCT00499018). One hundred and twenty-five DLBCL patients with tumour block available were analyzed. TP53 was mutated in 11/125 (9%) cases; 60/125 patients received high-dose chemoimmunotherapy up-front, as for the randomization arm; COO was reported in 88 patients: 48 germinal centre B-cell like, 25 activated B-cell like and 17 unclassified; 26 patients were double expressors in IHC and 11 double hit in FISH. After a median follow-up of 72 months, five-year failure-free survival (FFS) for TP53 mutated versus wild-type was 24% and 72%, and five-year overall survival (OS) was 34% and 83%, respectively. Adjusted hazard ratio (HR) was 2·28 [95% confidence interval (CI) 0·89-5·86, p = 0·086] and 4·05 (95% CI 1·37-11·97, p = 0·011) for FFS and OS, respectively. In this series of young DLBCL patients, TP53 gene mutation identified a poor prognosis subgroup, regardless of treatment and other biological markers.
引用
- Chiappella A, Diop F, Agostinelli C, et al. Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial. Br J Haematol. 2021. PMID: 34951009. doi:10.1111/bjh.17971
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。